Amyloidosis: Type the Protein Before Treating

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Assess cardiac risk, kidney trajectory, blood pressure, neuropathy, and treatment tolerance. Hematologic response and organ response may occur on different timelines.

Tissue contains amyloid: which protein is it?. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Tissue contains amyloid: which protein is it?. Confirm deposition — Interpret tissue in the clinical setting; Type the deposit — Protein typing identifies the disease pathway; Evaluate the clone separately — A monoclonal protein may coexist without being the deposit. Typing changes treatment. A circulating monoclonal protein alone does not prove AL amyloidosis. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Deposition is a pattern

Amyloid can involve kidneys, heart, nerves, and other tissues. Identifying deposits is only part of the diagnosis; the precursor protein determines treatment.

Recognize discordant clues

Proteinuria, restrictive cardiac features, autonomic symptoms, and a monoclonal protein can appear in different combinations. Absence of nephrotic proteinuria does not exclude systemic disease.

Order the complete monoclonal screen

Use serum free light chains plus serum immunofixation and urine immunofixation. Electrophoresis alone is not an adequate exclusion test. Interpret light-chain concentrations and ratio with kidney function; impaired clearance can elevate both chains.

Distinguish association from cause

MGUS can coexist with unrelated amyloidosis. A monoclonal protein or abnormal light-chain ratio alone does not establish AL amyloid as the tissue type.

Type deposits before clone-directed therapy

Congo-red-positive tissue establishes amyloid deposition, not its precursor. A coincidental monoclonal gammopathy does not prove AL. When type is uncertain, request validated tissue typing, including mass spectrometry when available, and reconcile the result with the monoclonal screen.

Watch organs, not only protein

Assess cardiac risk, kidney trajectory, blood pressure, neuropathy, and treatment tolerance. Hematologic response and organ response may occur on different timelines.

Supporting evidence

Continue learning